Global Allogeneic Cell Therapy Market Report 2023-2035: Celularity, Allogene Therapeutics, and Fate Therapeutics Driving Innovation, Heralding a New Era in Regenerative Medicine

Global Allogeneic Cell Therapy Market Report 2023-2035: Celularity, Allogene Therapeutics, and Fate Therapeutics Driving Innovation, Heralding a New Era in Regenerative Medicine

DUBLIN, Aug. 8, 2023 /PRNewswire/ — The “Allogeneic Cell Therapy: Global Market Report 2023-2035” report has been added to’s offering.

The global allogeneic cell therapy market is estimated at USD 900 million in 2023, and is projected to grow at a compounded annual growth rate (CAGR) of 14% during the forecast period, 2023 to 2035.

In the realm of regenerative medicine, the spotlight is firmly on allogeneic cell therapies – an innovative approach that promises to reshape how we treat various disorders. This comprehensive overview takes a deep dive into the forces driving this transformative field, ranging from the advantages of allogeneic therapies over autologous counterparts to the dynamic landscape of partnerships, clinical trials, and regional market trends.

Diverging Paths: Allogeneic vs. Autologous Cell Therapies

Allogeneic and autologous cell therapies represent distinct avenues within regenerative medicine. Autologous therapies involve using a patient’s own cells, which are processed and reintroduced. While personalized, this process is time-consuming. Allogeneic therapies, on the other hand, utilize donor cells that are readily available, scalable, and cost-effective. They eliminate the need for personalized production, ensuring uniform quality, lower costs, and the flexibility to approach different donors for subsequent treatments.

Pipeline and Clinical Insights: A Global Wave of Innovation

The allogeneic cell therapy market is in the midst of a significant wave of innovation, with a vast array of stakeholders driving the development of therapies for diverse indications. Currently, over 470 allogeneic cell therapies are under evaluation across different developmental stages. These therapies target a range of disorders from infectious diseases to neurological and oncological disorders, signaling the wide-reaching potential of allogeneic approaches.

Recent approvals, such as Gamida Cell’s Omisirge for hematologic malignancies, underscore the market’s momentum. As industry and non-industry players collaborate and clinical trial results continue to inspire confidence, the allogeneic cell therapy landscape is evolving at an accelerated pace.

Partnerships: The Catalysts of Innovation

Collaboration has become a cornerstone of the allogeneic cell therapy market’s growth. Companies are forming strategic partnerships to bolster research, development, and commercialization efforts. These alliances facilitate knowledge sharing, resource utilization, and access to complementary expertise, thereby accelerating the journey toward innovative allogeneic therapies.

For instance, Tessa Therapeutics’ collaboration with the US National Cancer Institute demonstrates the potential of collaborative ventures in advancing allogeneic therapies. Over 90 partnerships established since 2019 highlight the enthusiasm within the sector to push the boundaries of innovation collectively.

Investment and Funding: Nurturing Breakthroughs

Investor interest in the allogeneic cell therapy market is evident from the significant funds raised by companies engaged in this space. Over the last four years, approximately USD 8.8 billion has been invested globally. Venture rounds have played a pivotal role in funding, indicating the growing confidence in the market’s transformative potential.

This influx of funds not only fuels the development of allogeneic cell therapies but also spurs technological advancements and innovative breakthroughs.

Market Growth Factors: Challenges and Opportunities

Several factors drive the growth of the allogeneic cell therapy market. The ongoing dedication of industry and non-industry players, coupled with the prevalence of chronic and non-malignant disorders, is fostering the development and adoption of allogeneic therapies. Moreover, the challenges associated with producing autologous cell therapies, which are personalized and time-intensive, further underscore the transformative potential of allogeneic therapies.

Clinical Trials: Unveiling Efficacy and Safety

The robust allogeneic cell therapy landscape is supported by a plethora of clinical trials evaluating the effectiveness and safety of these therapies. Over 365 clinical trials are registered, targeting diverse indications such as hematologic malignancies, infectious diseases, neurological disorders, and more. North America dominates this arena, with around 55% of total enrollments.

The promising outcomes of clinical trials, like Allogene’s ALLO-715 allogeneic CAR T cell therapy for multiple myeloma, underscore the credibility of allogeneic cell therapies and their potential to revolutionize treatment approaches.

Regional Market Insights: North America’s Leadership

With a thriving ecosystem of allogeneic cell therapy developers, North America is poised to capture over 60% of the global market share by 2035. Rising disease prevalence, FDA approvals, and government support for reimbursement are propelling the region’s market growth. The government’s recognition of allogeneic cell therapies’ transformative potential in enhancing patient outcomes is a testament to the industry’s impact.

Key Players and Prospects for the Future

Numerous key players are actively pushing the boundaries of allogeneic cell therapies, targeting diverse indications. Players like Celularity, Allogene Therapeutics, and Fate Therapeutics are driving innovation. As these players continue to innovate and gain approvals, the allogeneic cell therapy market is on track for substantial growth, heralding a new era in regenerative medicine.

Allogeneic Cell Therapy Market Research Conclusion

The global allogeneic cell therapy market is in the midst of a remarkable journey, fueled by innovation, collaboration, investment, and promising clinical trial results. Allogeneic therapies hold the potential to revolutionize healthcare delivery through their immediate availability, scalability, and cost-effectiveness. With industry and non-industry players relentlessly pushing boundaries, the allogeneic cell therapy market is primed for robust growth, ushering in a new era of possibilities in regenerative medicine.

Key Topics Covered

1.1. Allogeneic Cell Therapy Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines


3.1. Overview of Allogeneic Cell Therapy
3.2. Manufacturing Process of Allogeneic Cell Therapy
3.3. Advantages Offered by Allogeneic Cell Therapy
3.4. Challenges Associated with Allogeneic Cell Therapy
3.5. Recent Developments in Allogeneic Cell Therapy Industry
3.6. Future Perspectives

4.1. Allogeneic Cell Therapies: Market Landscape
4.2. Allogeneic Cell Therapies: Developer Landscape

5.1. Chapter Overview
5.2. Partnership Models
5.2. Allogeneic Cell Therapies: Partnerships and Collaborations

6.1. Chapter Overview
6.2. Types of Funding
6.3. Allogeneic Cell Therapies: Funding and Investments

7.1. Analysis Methodology and Key Parameters
7.2. Allogeneic Cell Therapies: Clinical Trial Analysis

8.1. Methodology and Key Parameters
8.2. Allogeneic Cell Therapies: Key Opinion Leaders (KOLs)

9.1. Chapter Overview
9.2. Forecast Methodology and Key Assumptions
9.3. Global Allogeneic Cell Therapy Market, 2023-2035
9.4. Allogeneic Cell Therapy Market: Product-wise Sales Forecast, 2023-2035

10.1. Chapter Overview
10.2. Mesoblast
10.3. Triumvira Immunologics



Companies Mentioned (378 Total)

For more information about this report visit

About is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716